[
  {
    "ts": "2026-02-13T10:40:02+00:00",
    "headline": "Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets",
    "summary": "Last week saw the newest yearly earnings release from Gilead Sciences, Inc. ( NASDAQ:GILD ), an important milestone in...",
    "url": "https://finance.yahoo.com/news/gilead-sciences-inc-nasdaq-gild-104002543.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "6598793a-43bc-329f-9f82-cd2637f2cc25",
      "content": {
        "id": "6598793a-43bc-329f-9f82-cd2637f2cc25",
        "contentType": "STORY",
        "title": "Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets",
        "description": "",
        "summary": "Last week saw the newest yearly earnings release from Gilead Sciences, Inc. ( NASDAQ:GILD ), an important milestone in...",
        "pubDate": "2026-02-13T10:40:02Z",
        "displayTime": "2026-02-13T10:40:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAEiJmFsYXJTRBPxnneP6w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXB9F2qU7k4qk3_k1DQd9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-inc-nasdaq-gild-104002543.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-inc-nasdaq-gild-104002543.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:57:41+00:00",
    "headline": "BofA Raises PT on Gilead Sciences (GILD) to $162 From $154 – Here’s Why",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical research stocks to buy according to hedge funds. On February 11, BofA lifted the price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $162 from $154, maintaining a Buy rating on the shares. The firm told investors in a post-earnings note that it is confident in […]",
    "url": "https://finance.yahoo.com/news/bofa-raises-pt-gilead-sciences-145741484.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "38c3ce5f-02a2-33a9-89f8-31fb7277108e",
      "content": {
        "id": "38c3ce5f-02a2-33a9-89f8-31fb7277108e",
        "contentType": "STORY",
        "title": "BofA Raises PT on Gilead Sciences (GILD) to $162 From $154 – Here’s Why",
        "description": "",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical research stocks to buy according to hedge funds. On February 11, BofA lifted the price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $162 from $154, maintaining a Buy rating on the shares. The firm told investors in a post-earnings note that it is confident in […]",
        "pubDate": "2026-02-13T14:57:41Z",
        "displayTime": "2026-02-13T14:57:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ha22PhpGlsEhK3tmOzGDVw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CkBvnQJGKRIUyIDAWZszGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bofa-raises-pt-gilead-sciences-145741484.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bofa-raises-pt-gilead-sciences-145741484.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:36:00+00:00",
    "headline": "Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?",
    "summary": "Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.",
    "url": "https://finance.yahoo.com/news/gileads-hiv-portfolio-sustain-growth-143600503.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "ac87d707-61ed-3773-a205-93ac5c80ea41",
      "content": {
        "id": "ac87d707-61ed-3773-a205-93ac5c80ea41",
        "contentType": "STORY",
        "title": "Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?",
        "description": "",
        "summary": "Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.",
        "pubDate": "2026-02-13T14:36:00Z",
        "displayTime": "2026-02-13T14:36:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tEjPL1xniTl4Yv5crLKiVw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3wQ5IrbXljgjZ16xqKRVcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gileads-hiv-portfolio-sustain-growth-143600503.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gileads-hiv-portfolio-sustain-growth-143600503.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]